ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer

Not Applicable

Completed

Conditions: Lung Cancer
Precancerous Condition
Tobacco Use Disorder

Interventions: Drug: calcitriol
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2008-06-05

Last Posted Date: 2018-06-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00690924

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Phase 2

Terminated

Conditions: Gastric Cancer

Interventions: Drug: docetaxel
Drug: vandetanib

First Posted Date: 2008-05-23

Last Posted Date: 2015-01-08

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT00683787

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: HPPH
Procedure: laser therapy

First Posted Date: 2008-05-09

Last Posted Date: 2018-10-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00675233

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer

Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: HPPH

First Posted Date: 2008-05-01

Last Posted Date: 2016-03-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 11

Registration Number: NCT00670397

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Lymphoproliferative Disorder
Small Intestine Cancer
Lymphoma

First Posted Date: 2008-03-28

Last Posted Date: 2011-03-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 7

Registration Number: NCT00646139

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Dietary Supplement: selenomethionine
Drug: capecitabine
Drug: oxaliplatin
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Radiation: radiation therapy

First Posted Date: 2008-02-28

Last Posted Date: 2017-11-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 5

Registration Number: NCT00625183

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Anastrozole
Dietary Supplement: flaxseed

First Posted Date: 2008-02-11

Last Posted Date: 2017-10-12

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 28

Registration Number: NCT00612560

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Phase 1

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2007-11-19

Last Posted Date: 2022-10-03

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00560495

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy

Not Applicable

Withdrawn

Conditions: Prostate Cancer

First Posted Date: 2007-11-16

Last Posted Date: 2013-02-01

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00559481

DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Dietary Supplement: cholecalciferol
Genetic: polymerase chain reaction
Genetic: polymorphism analysis
Genetic: protein expression analysis
Genetic: reverse transcriptase-polymerase chain reaction
Genetic: western blotting
Other: high performance liquid chromatography
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: adjuvant therapy
Procedure: immunoscintigraphy

First Posted Date: 2007-10-30

Last Posted Date: 2017-04-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 50

Registration Number: NCT00550563

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy